LiDCO Group plc announces the appointment of Tim Hall to the Board as Chief Financial Officer (CFO) and Company Secretary with effect from March 11, 2019. Tim was CFO of Oxford Gene Technology from 2012 until shortly after its recent acquisition by Sysmex Corporation. Prior to this, Tim was Finance Director at AIM-listed Lombard Medical Technologies PLC for six years and previously had senior finance roles in UCB S.A, Celltech Group plc and Medeva PLC.

Tim's early career included finance and project management roles at Glaxo Wellcome plc/Wellcome plc. Tim qualified as a Chartered Accountant with Touche Ross & Co, now Deloitte. Tim succeeds Jill McGregor who, as previously announced, leaves LiDCO on 22 March 2019.